Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reck

Showing results (21-30 of 1,722) with videos related to

Pageof 173
Sort By:
Immunotherapy|November 18, 2017
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancerMartin Reck
Anticancer Research|July 22, 2005
Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)Martin Reck
Anatomischer Anzeiger|January 1, 1971
[Structure of the muscularis propria on the passage from the small intestine to Meckel's diverticulum]W Reck
Laryngologie, Rhinologie, Otologie|December 1, 1986
[Therapeutic limits of endonasal fenestration of the maxillary sinus]R Reck
HNO|April 1, 1985
[5 years of clinical experience with Ceravital prostheses in the middle ear]R Reck
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 13, 2003
[out of scope]Simone Reck
Pneumologie (Stuttgart, Germany)|December 9, 2016
M Reck
Future Oncology (London, England)|March 25, 2006
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLCMartin Reck
Versicherungsmedizin|March 24, 2006
[Chronic back pain and expert opinion (II)]R Reck
Onkologie|September 25, 2007
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case seriesMartin Reck
Pageof 173

Showing results (21-30 of 1,722) with videos related to

Sort By:
Pageof 173
Immunotherapy|November 18, 2017
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancerMartin Reck
Anticancer Research|July 22, 2005
Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)Martin Reck
Anatomischer Anzeiger|January 1, 1971
[Structure of the muscularis propria on the passage from the small intestine to Meckel's diverticulum]W Reck
Laryngologie, Rhinologie, Otologie|December 1, 1986
[Therapeutic limits of endonasal fenestration of the maxillary sinus]R Reck
HNO|April 1, 1985
[5 years of clinical experience with Ceravital prostheses in the middle ear]R Reck
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 13, 2003
[out of scope]Simone Reck
Pneumologie (Stuttgart, Germany)|December 9, 2016
M Reck
Future Oncology (London, England)|March 25, 2006
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLCMartin Reck
Versicherungsmedizin|March 24, 2006
[Chronic back pain and expert opinion (II)]R Reck
Onkologie|September 25, 2007
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case seriesMartin Reck
Pageof 173